Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1998-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.42.7.1620PMID 9660994PMCID PMC105656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

  1998cited by this paper
• In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine

  1997cited by this paper
• Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years

  1997influential reference
• Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma

  1997cited by this paper
• The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.

  1997cited by this paper
• Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

  1997cited by this paper
• Novel approaches to three drug antiretroviral therapy for HIV infection in 1997

  1997cited by this paper
• Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

  1997influential reference
• Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients

  1996influential reference
• Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.

  1996cited by this paper
• Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.

  1996cited by this paper
• Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase

  1996cited by this paper
• In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).

  1996influential reference
• An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine

  1996cited by this paper
• Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay

  1996cited by this paper
• Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.

  1996cited by this paper
• Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro

  1996cited by this paper
• Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

  1995cited by this paper
• K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

  1995cited by this paper
• Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

  1995cited by this paper
• Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

  1995cited by this paper
• Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells

  1995cited by this paper
• Kinetic Interaction of the Diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and Other anti-HIV Active Purine Congeners with HIV Reverse Transcriptase and Human DNA Polymerases α, β and γ

  1995cited by this paper
• Kinetic Properties of Adenine Nucleotide Analogues Against Purified 5-Phosphoribosyl-1-pyrophosphate Synthetases from E. coli, Rat Liver and Human Erythrocytes

  1995cited by this paper
• Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells

  1995cited by this paper
• Drug Resistance and Heterogeneous Long-Term Virologic Responses of Human Immunodeficiency Virus Type 1-Infected Subjects to Zidovudine and Didanosine Combination Therapy

  1995cited by this paper
• Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy

  1995cited by this paper
• Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy

  1995cited by this paper
• Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.

  1995cited by this paper
• Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

  1995cited by this paper
• Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.

  1995cited by this paper
• Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment.

  1995cited by this paper
• Development of HIV‐1 resistance to (−)2′‐deoxy‐3′‐thiacytidine in patients with AIDS or advanced AIDS‐related complex

  1995cited by this paper
• Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates

  1994cited by this paper
• Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

  1994cited by this paper
• Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

  1994cited by this paper
• Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

  1994influential reference
• Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

  1994cited by this paper
• Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

  1994cited by this paper
• Didanosine Resistance in HIV-infected Patients Switched from Zidovudine to Didanosine Monotherapy

  1994cited by this paper
• The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

  1993cited by this paper
• Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

  1993cited by this paper
• Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

  1993cited by this paper
• Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

  1992influential reference
• Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

  1992cited by this paper
• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

  1992cited by this paper
• 5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives.

  1991cited by this paper
• Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes.

  1991influential reference
• Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

  1991cited by this paper
• Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound.

  1991influential reference
• Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

  1989cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper
• Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy

  1989cited by this paper
• Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

  1988cited by this paper
• Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines.

  1987cited by this paper
• A novel selective broad-spectrum anti-DNA virus agent

  1986cited by this paper

• Adefovir Dipivoxil

  2012cites this paper
• Human Immunodeficiency Virus

  2010cites this paper
• National survey of the prevalence and conditions of selection of HIV‐1 reverse transcriptase K70E mutation

  2008cites this paper
• Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection

  2007cites this paper
• Novel Drug Resistance Pattern Associated with the Mutations K70G and M184V in Human Immunodeficiency Virus Type 1 Reverse Transcriptase

  2007cites this paper
• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond

  2006cites this paper
• Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors

  2006cites this paper
• Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

  2005cites this paper
• The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients.

  2005cites this paper
• Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

  2005cites this paper
• Adefovir dipivoxil: review of a novel acyclic nucleoside analogue

  2004cites this paper
• Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment

  2004cites this paper
• Comparisons of the Hbv and HIV Polymerase, and Antiviral Resistance Mutations

  2003cites this paper
• Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

  2003cites this paper
• Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine

  2002cites this paper
• Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

  2002cites this paper
• Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort

  2001cites this paper
• Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort.

  2001cites this paper
• Factores inmunitarios protectivos del huésped contra la infección por el VIH-1 y la progresión a SIDA: quimiocinas y sus receptores.

  2001cites this paper
• Resistance of Hepatitis B Virus to Antiviral Drugs: Current Aspects and Directions for Future Investigation

  2001cites this paper
• Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

  2001cites this paper
• Adefovir and Tenofovir Susceptibilities of HIV‐1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS‐96‐408

  2001cites this paper
• Effect of PMPA and PMEA on the Kinetics of Viral Load in Simian Immunodeficiency Virus-Infected Macaques

  2000cites this paper
• Resistance against reverse transcriptase inhibitors.

  2000cites this paper
• Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)

  2000cites this paper
• Inhibitors of HIV-1 reverse transcriptase.

  2000cites this paper
• Case studies of the hepatitis B patient: a panel discussion.

  2000cites this paper
• Inhibitors of HIV- I reverse transcriptase

  2000cites this paper
• Strategies for second-line antiretroviral therapy in adults with HIV infection.

  1999cites this paper
• Antiretroviral drug resistance in HIV-1

  1999cites this paper
• 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA

  1999cites this paper
• Coming therapies: adefovir.

  1999cites this paper
• Early Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques

  1999cites this paper
• Review article Perspectives for the treatment of hepatitis B virus infections

  1999cites this paper
• Perspectives for the treatment of hepatitis B virus infections.

  1999cites this paper
• Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.

  1999cites this paper
• Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B

  1999cites this paper
• In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA

  1998cites this paper
• New antivirals - mechanism of action and resistance development.

  1998cites this paper
• Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

  1998cites this paper